title: Minimal residual disease in breast cancer: in blood veritas.
abstract: A blood-based molecular test might direct recommendations for systemic therapies in patients with early-stage breast cancer undergoing surgery with curative intent. A new study suggests that droplet digital PCR (ddPCR) can be used to detect cancer-specific DNA alterations in plasma with sensitivity suitable for monitoring minimal residual disease.
authors.affiliation: Authors' Affiliations: Department of Oncology, University of Turin; Candiolo Cancer Institute-FPO, IRCCS, Turin; and FIRC Institute of Molecular Oncology (IFOM), Milan, ItalyAuthors' Affiliations: Department of Oncology, University of Turin; Candiolo Cancer Institute-FPO, IRCCS, Turin; and FIRC Institute of Molecular Oncology (IFOM), Milan, Italy.
authors.forename: Giulia
authors.initials: G
authors.lastname: Siravegna
authors.affiliation: Authors' Affiliations: Department of Oncology, University of Turin; Candiolo Cancer Institute-FPO, IRCCS, Turin; and FIRC Institute of Molecular Oncology (IFOM), Milan, ItalyAuthors' Affiliations: Department of Oncology, University of Turin; Candiolo Cancer Institute-FPO, IRCCS, Turin; and FIRC Institute of Molecular Oncology (IFOM), Milan, ItalyAuthors' Affiliations: Department of Oncology, University of Turin; Candiolo Cancer Institute-FPO, IRCCS, Turin; and FIRC Institute of Molecular Oncology (IFOM), Milan, Italy alberto.bardelli@ircc.it.
authors.forename: Alberto
authors.initials: A
authors.lastname: Bardelli
mesh_terms: D001943:Breast Neoplasms / Q000175:diagnosis* / Q000235:genetics*; D004273:DNA, Neoplasm / Q000097:blood* / Q000235:genetics*; D005260:Female; D006801:Humans
chemical_list: D004273:DNA, Neoplasm